ClinicalTrials.gg
CompletedNCT02505334Updated Sep 5, 2018Results posted

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

A Phase 3 interventional study of liraglutide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 47 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
14th of 151
635 · median 62
Started
2015
with 7 others
Phase 3
45 of 151
1 open now
Registered
107th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 8 that started in 2015, is one of 45 in phase 3, and was the 107th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 635 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese subjects at least 20 years of age at the time of
  • Type 2 diabetes subjects (diagnosed clinically) for at least 6 months prior to screening
  • 7.5-10.0% [58 mmol/mol-86 mmol/mol] (both inclusive)
  • Subjects on stable therapy with one OAD (oral antidiabetic drug) (stable therapy is defined as unchanged medication and unchanged dose) for for at least 60 days before screening according to approved Japanese labelling

Exclusion criteria

Exclusion Criteria:

  • Treatment with insulin within 12 weeks prior to screening
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening
  • Screening calcitonin equal or above 50 ng/l
  • History of pancreatitis (acute or chronic)
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Subjects presently classified as being in (NYHA) Class IV
  • Within the past 180 days any of the following: myocardial infarction, stroke or hospitalisation for unstable angina and/or
  • Diagnosis of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer, polyps and in-situ carcinomas)
  • Any condition which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
635 participants (actual)

Study arms

  • Experimental
    Liraglutide 1.8 mg

    The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.

    Drug: liraglutide

  • Active comparator
    Liraglutide 0.9 mg

    The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.

    Drug: liraglutide

Interventions

  • Injected subcutaneously s.c. (under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) (Week 26)

    Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of treatment. The change from baseline in the response after 26 weeks of treatment is analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline response as a covariate.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in HbA1c (Week 52)

    Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment.

    Time frame: Week 0, Week 52

  2. Responder for HbA1c Below 7.0% (53 mmol/Mol)

    Reported results are number of subjects who achieved HbA1c target below 7.0% after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  3. Responder for HbA1c Below or Equal to 6.5% (48 mmol/Mol)

    Reported results are number of subjects who achieved HbA1c target below or equal to 6.5% after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  4. Responder for HbA1c Below 7.0% Without Weight Gain

    Reported results are number of subjects who achieved HbA1c target below 7.0% without weight gain after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  5. Responder for HbA1c Below 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes

    Reported results are subjects with HbA1c \<7.0% after 26 weeks and 52 weeks of treatment, respectively without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. Severe or BG confirmed symptomatic hypoglycaemia: severe as per ADA classification or BG confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA: episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk)0) and no later than 7 days after the last day on liraglutide (maximum till wk26+7days and wk52+7days). Hence, the following shown 'Time Frame' should be read as 'Wk26+7days and Wk52+7days'

    Time frame: Week 26 and Week 52

  6. Change in Self-Measured Blood Glucose (SMBG) 7-point Profile: 7-point Profile (Individual Points in the Profile)

    Reported results are 7-point SMBG values at week 0, week 26 and week 52. The 7-point profile blood glucose levels were measured at the following time points always starting with the first: 1. Before breakfast. 2. 90 minutes after start of breakfast. 3. Before lunch. 4. 90 minutes after start of lunch. 5. Before dinner. 6. 90 minutes after start of dinner. 7. At bedtime.

    Time frame: Week 0 and Week 26 and Week 52

  7. Change in SMBG 7-point Profile: Mean of 7-point Profile

    Change from baseline (week 0) in mean of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  8. Change in SMBG 7-point Profile: Mean of Postprandial Increments (From Before Meal to 90 Minutes After for Breakfast, Lunch and Dinner)

    Change from baseline (week 0) in mean of postprandial increments (from before meal to 90 minutes after for breakfast, lunch and dinner) of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  9. Change in Fasting Plasma Glucose (FPG)

    Change from baseline (week 0) in FPG was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  10. Change in Waist Circumference

    Change from baseline (week 0) in waist circumference was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  11. Change in Body Weight

    Change from baseline (week 0) in body weight was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  12. Change in Body Mass Index (BMI)

    Change from baseline (week 0) in BMI was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  13. Change in Blood Pressure (Systolic and Diastolic)

    Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  14. Fasting C-peptide

    Fasting C-peptide was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  15. Fasting Insulin

    Fasting insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  16. Fasting Glucagon

    Fasting glucagon was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  17. Proinsulin

    Proinsulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  18. Proinsulin/Insulin

    Proinsulin/insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  19. Homeostasis Model Assessment of Beta-cell Function (HOMA-B)

    HOMA-B was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B=\[(20 x fasting insulin in µU/mL)/(FPG in mmol/L-3.5)\].

    Time frame: Week 26 and Week 52

  20. Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)

    HOMA-IR was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-IR is an index of insulin resistance and was calculated as: HOMA-IR= fasting insulin (μU/mL) x FPG (mmol/L)/22.5.

    Time frame: Week 26 and Week 52

  21. Total Cholesterol

    Total cholesterol was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  22. Low Density Lipoprotein (LDL) Cholesterol

    LDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  23. High Density Lipoprotein (HDL) Cholesterol

    HDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  24. Very Low Density Lipoprotein (VLDL) Cholesterol

    VLDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  25. Triglycerides

    Triglycerides were evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  26. Free Fatty Acids

    Free fatty acids were evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 26 and Week 52

  27. Number of Treatment Emergent Adverse Events

    Treatment emergent adverse events (TEAEs) were evaluated during the 26-week and 52-week treatment period, respectively. TEAE for weeks 0-26: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 26 + 7 days). TEAE for weeks 0-52: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 52 + 7 days). Hence, the following shown 'Time Frame' should be read as 'Weeks 0-26 + 7 days and Weeks 0-52 + 7 days'.

    Time frame: Weeks 0-26 and Weeks 0-52

  28. Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the 26-week and 52-week treatment period, respectively. Severe or BG confirmed symptomatic hypoglycaemia (hypo):An episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypo. ADA definition of severe hypo:episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk) 0) and no later than 7 days after the last day on liraglutide (maximum till wk 26 and wk 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'wk 0-26+7 days and wk 0-52+7 days'.

    Time frame: Weeks 0-26 and Weeks 0-52

  29. Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the26-week and 52-week treatment period, respectively. Nocturnal hypoglycaemic episodes: Those occurring between 00:01 and 05:59 hours, both inclusive. Severe or BG confirmed symptomatic hypoglycaemia: episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Treatment emergent: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.

    Time frame: Weeks 0-26 and Weeks 0-52

  30. Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition

    American Diabetes Association (ADA) classification of hypoglycaemia: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG level ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG level ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG level \>3.9 mmol/L with symptoms. Treatment emergent hypoglycaemic episode: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.

    Time frame: Weeks 0-26 and Weeks 0-52

  31. Change in Pulse

    Change from baseline (week 0) in pulse was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  32. Change in Physical Examination

    Reported results are physical examination outcomes at week (wk) 0, wk 26 and wk 52. Physical examination consisted of the following listed examinations and the outcome of each examination was evaluated as: 1) normal, 2) abnormal, not clinically significant (NCS) or 3) abnormal, clinically significant (CS). 1. Cardiovascular system 2. Central and peripheral nervous system (PNS) 3. Gastrointestinal (GI) system including mouth 4. General appearance 5. Head, ears, eyes, nose, throat, neck 6. Lymph node palpation 7. Musculoskeletal system 8. Respiratory system 9. Skin 10. Thyroid gland

    Time frame: Week 0 and Week 26 and Week 52

  33. Change in Eye Examination

    Reported results are eye examination (ophthalmoscopy) outcomes at week 0, week 26 and week 52. Ophthalmoscopy outcomes for both left and right eye were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.

    Time frame: Week 0 and Week 26 and Week 52

  34. Change in Electrocardiogram (ECG)

    Reported results are ECG outcomes at week 0, week 26 and week 52. ECG outcomes were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.

    Time frame: Week 0 and Week 26 and Week 52

  35. Change in Biochemistry: Creatinine

    Change from baseline (week 0) in creatinine was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  36. Change in Biochemistry: eGFR

    Change from baseline (week 0) in estimated glomerular filtration rate (eGFR) was evaluated after 26 weeks and 52 weeks of treatment, respectively. eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, mL/min/1.73m\^2.

    Time frame: Week 0, Week 26, Week 52

  37. Change in Biochemistry: Alanine Aminotransferase

    Change from baseline (week 0) in alanine aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  38. Change in Biochemistry: Aspartate Aminotransferase

    Change from baseline (week 0) in aspartate aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  39. Change in Biochemistry: Alkaline Phosphatase

    Change from baseline (week 0) in alkaline phosphatase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  40. Change in Biochemistry: Sodium

    Change from baseline (week 0) in sodium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  41. Change in Biochemistry: Potassium

    Change from baseline (week 0) in potassium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  42. Change in Biochemistry: Albumin

    Change from baseline (week 0) in albumin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  43. Change in Biochemistry: Total Bilirubin

    Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  44. Change in Biochemistry: Urea

    Change from baseline (week 0) in urea was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  45. Change in Biochemistry: Creatine Kinase

    Change from baseline (week 0) in creatine kinase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  46. Change in Biochemistry: Calcium

    Change from baseline (week 0) in calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  47. Change in Biochemistry: Albumin Corrected Calcium

    Change from baseline (week 0) in albumin corrected calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  48. Change in Biochemistry: Amylase

    Change from baseline (week 0) in amylase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  49. Change in Biochemistry: Lipase

    Change from baseline (week 0) in lipase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  50. Change in Haematology: Haemoglobin

    Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26, Week 52

  51. Change in Haematology: Haematocrit

    Change from baseline (week 0) in haematocrit was evaluated after 26 weeks and 52 weeks of treatment, respectively. Haematocrit is the ratio of the volume of red blood cells to the total volume of blood.

    Time frame: Week 0, Week 26, Week 52

  52. Change in Haematology: Thrombocytes

    Change from baseline (week 0) in thrombocytes (platelets) was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  53. Change in Haematology: Erythrocytes

    Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  54. Change in Haematology: Leukocytes

    Change from baseline (week 0) in leukocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  55. Change in Haematology: Eosinophils

    Change from baseline (week 0) in eosinophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  56. Change in Haematology: Neutrophils

    Change from baseline (week 0) in neutrophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  57. Change in Haematology: Basophils

    Change from baseline (week 0) in basophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  58. Change in Haematology: Monocytes

    Change from baseline (week 0) in monocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  59. Change in Haematology: Lymphocytes

    Change from baseline (week 0) in lymphocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

    Time frame: Week 0, Week 26 and Week 52

  60. Change in Calcitonin

    Reported results are number of subjects with low, normal or high calcitonin values at week 0, week 26 and week 52. Number of subjects analyzed = number of subjects contributed to the analysis for individual time point. Calcitonin values were categorised as low, normal or high.

    Time frame: Week 0 and Week 26 and Week 52

08

Results

Posted Jun 25, 2018

Participant flow

The trial was conducted at 47 sites in Japan: 47 sites screened and 45 of them randomised subjects. After screening, 635 subjects entered into the 12-week run-in period.

Main Treatment Period
Participant flow — Main Treatment Period
MilestoneLiraglutide 1.8 mgLiraglutide 0.9 mg
Started233233
Completed218194
Not completed1539
Withdrew: Adverse event33
Withdrew: Lack of efficacy717
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject18
Withdrew: Unclassified410
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneLiraglutide 1.8 mgLiraglutide 0.9 mg
Started2120
Completed1940
Not completed180
Withdrew: Adverse event50
Withdrew: Lack of efficacy40
Withdrew: Withdrawal by subject60
Withdrew: Unclassified30

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c) (Week 26)

Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of treatment. The change from baseline in the response after 26 weeks of treatment is analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline response as a covariate.

Time frame:
Week 0, Week 26
Reported as:
Least squares mean · Percentage (%) of HbA1c
Change in Glycosylated Haemoglobin (HbA1c) (Week 26)
Percentage (%) of HbA1cLiraglutide 1.8 mgLiraglutide 0.9 mg
Change in Glycosylated Haemoglobin (HbA1c) (Week 26)-0.23 ± 0.060.17 ± 0.06
Statistical analysis
  • Liraglutide 1.8 mg vs Liraglutide 0.9 mg · ANCOVA · p = <0.0001 · Treatment difference: -0.40 · 95% CI -0.55 to -0.24
SecondaryChange in HbA1c (Week 52)

Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment.

Time frame:
Week 0, Week 52
Reported as:
Mean · Percentage (%) of HbA1c
Change in HbA1c (Week 52)
Percentage (%) of HbA1cLiraglutide 1.8 mg
Week 0: Baseline8.14 ± 1.02
Week 52: Change from baseline-0.09 ± 1.05
SecondaryResponder for HbA1c Below 7.0% (53 mmol/Mol)

Reported results are number of subjects who achieved HbA1c target below 7.0% after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Count of participants · Participants
Responder for HbA1c Below 7.0% (53 mmol/Mol)
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 265318
Week 5245—
SecondaryResponder for HbA1c Below or Equal to 6.5% (48 mmol/Mol)

Reported results are number of subjects who achieved HbA1c target below or equal to 6.5% after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Count of participants · Participants
Responder for HbA1c Below or Equal to 6.5% (48 mmol/Mol)
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 26185
Week 5216—
SecondaryResponder for HbA1c Below 7.0% Without Weight Gain

Reported results are number of subjects who achieved HbA1c target below 7.0% without weight gain after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Count of participants · Participants
Responder for HbA1c Below 7.0% Without Weight Gain
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 263613
Week 5235—
SecondaryResponder for HbA1c Below 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes

Reported results are subjects with HbA1c \<7.0% after 26 weeks and 52 weeks of treatment, respectively without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. Severe or BG confirmed symptomatic hypoglycaemia: severe as per ADA classification or BG confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA: episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk)0) and no later than 7 days after the last day on liraglutide (maximum till wk26+7days and wk52+7days). Hence, the following shown 'Time Frame' should be read as 'Wk26+7days and Wk52+7days'

Time frame:
Week 26 and Week 52
Reported as:
Count of participants · Participants
Responder for HbA1c Below 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 265318
Week 5245—
SecondaryChange in Self-Measured Blood Glucose (SMBG) 7-point Profile: 7-point Profile (Individual Points in the Profile)

Reported results are 7-point SMBG values at week 0, week 26 and week 52. The 7-point profile blood glucose levels were measured at the following time points always starting with the first: 1. Before breakfast. 2. 90 minutes after start of breakfast. 3. Before lunch. 4. 90 minutes after start of lunch. 5. Before dinner. 6. 90 minutes after start of dinner. 7. At bedtime.

Time frame:
Week 0 and Week 26 and Week 52
Reported as:
Mean · mg/dL
Change in Self-Measured Blood Glucose (SMBG) 7-point Profile: 7-point Profile (Individual Points in the Profile)
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Before breakfast181.8 ± 42.8177.1 ± 43.4
Week 0: 90 minutes after start of breakfast262.6 ± 65.0266.5 ± 70.0
Week 0: Before lunch169.5 ± 57.7177.6 ± 61.7
Week 0: 90 minutes after start of lunch253.1 ± 64.5252.2 ± 63.5
Week 0: Before dinner173.4 ± 59.2169.7 ± 56.5
Week 0: 90 minutes after start of dinner254.3 ± 66.2249.5 ± 63.2
Week 0: At bedtime226.1 ± 67.4217.8 ± 58.7
Week 26: Before breakfast171.7 ± 39.6178.2 ± 44.4
Week 26: 90 minutes after start of breakfast247.2 ± 64.6258.2 ± 63.7
Week 26: Before lunch161.2 ± 51.0177.0 ± 57.9
Week 26: 90 minutes after start of lunch234.7 ± 63.3255.3 ± 66.7
Week 26: Before dinner162.3 ± 47.5168.6 ± 57.5
Week 26: 90 minutes after start of dinner233.3 ± 60.1251.5 ± 64.9
Week 26: At bedtime205.6 ± 58.6220.5 ± 68.8
Week 52: Before breakfast176.1 ± 43.2—
Week 52: 90 minutes after start of breakfast251.1 ± 69.1—
Week 52: Before lunch169.6 ± 59.7—
Week 52: 90 minutes after start of lunch243.3 ± 63.9—
Week 52: Before dinner164.3 ± 50.8—
Week 52: 90 minutes after start of dinner240.5 ± 65.8—
Week 52: At bedtime207.9 ± 66.7—
SecondaryChange in SMBG 7-point Profile: Mean of 7-point Profile

Change from baseline (week 0) in mean of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in SMBG 7-point Profile: Mean of 7-point Profile
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Baseline (week 0)217.9 ± 46.7217.7 ± 46.8
Change from baseline: week 26-14.5 ± 39.0-0.6 ± 45.0
Change from baseline: week 52-8.9 ± 43.7—
SecondaryChange in SMBG 7-point Profile: Mean of Postprandial Increments (From Before Meal to 90 Minutes After for Breakfast, Lunch and Dinner)

Change from baseline (week 0) in mean of postprandial increments (from before meal to 90 minutes after for breakfast, lunch and dinner) of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in SMBG 7-point Profile: Mean of Postprandial Increments (From Before Meal to 90 Minutes After for Breakfast, Lunch and Dinner)
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline81.7 ± 38.781.6 ± 38.6
Week 26: Change from baseline-8.4 ± 43.8-1.5 ± 39.5
Week 52: Change from baseline-6.3 ± 44.4—
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline (week 0) in FPG was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose (FPG)
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline172.5 ± 38.7172.0 ± 38.3
Week 26: Change from baseline-8.4 ± 36.71.0 ± 33.7
Week 52: Change from baseline-1.2 ± 39.0—
SecondaryChange in Waist Circumference

Change from baseline (week 0) in waist circumference was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · Centimeter (cm)
Change in Waist Circumference
Centimeter (cm)Liraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline93.68 ± 11.7593.82 ± 11.50
Week 26: Change from baseline-0.44 ± 3.04-0.73 ± 3.03
Week 52: Change from baseline-1.07 ± 3.64—
SecondaryChange in Body Weight

Change from baseline (week 0) in body weight was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · Kilogram (kg)
Change in Body Weight
Kilogram (kg)Liraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline74.67 ± 15.2475.13 ± 16.46
Week 26: Change from baseline-0.77 ± 2.01-0.95 ± 2.19
Week 52: Change from baseline-1.05 ± 2.26—
SecondaryChange in Body Mass Index (BMI)

Change from baseline (week 0) in BMI was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · kg/m^2
Change in Body Mass Index (BMI)
kg/m^2Liraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline27.34 ± 4.8027.20 ± 4.72
Week 26: Change from baseline-0.28 ± 0.72-0.33 ± 0.78
Week 52: Change from baseline-0.39 ± 0.82—
SecondaryChange in Blood Pressure (Systolic and Diastolic)

Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mmHg
Change in Blood Pressure (Systolic and Diastolic)
mmHgLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: SBP, Baseline128.0 ± 13.1128.8 ± 13.1
Week 26: SBP, change from baseline-1.7 ± 12.80.4 ± 12.2
Week 52: SBP, change from baseline-0.9 ± 12.5—
Week 0: DBP, Baseline79.6 ± 9.180.3 ± 9.8
Week 26: DBP, change from baseline-0.9 ± 8.70.1 ± 7.8
Week 52: DBP, change from baseline-0.6 ± 8.4—
SecondaryFasting C-peptide

Fasting C-peptide was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · ng/mL
Fasting C-peptide
ng/mLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 261.946 ± 41.91.853 ± 40.8
Week 521.906 ± 42.2—
SecondaryFasting Insulin

Fasting insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · pmol/L
Fasting Insulin
pmol/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2677.00 ± 70.970.91 ± 65.3
Week 5277.31 ± 68.7—
SecondaryFasting Glucagon

Fasting glucagon was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · pmol/L
Fasting Glucagon
pmol/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2622.5 ± 30.023.4 ± 26.8
Week 5223.4 ± 30.2—
SecondaryProinsulin

Proinsulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · pmol/L
Proinsulin
pmol/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2615.638 ± 111.216.054 ± 101.8
Week 5216.217 ± 107.4—
SecondaryProinsulin/Insulin

Proinsulin/insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · Percentage (%) of proinsulin/insulin
Proinsulin/Insulin
Percentage (%) of proinsulin/insulinLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2620.31 ± 70.722.64 ± 70.6
Week 5220.98 ± 72.5—
SecondaryHomeostasis Model Assessment of Beta-cell Function (HOMA-B)

HOMA-B was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B=\[(20 x fasting insulin in µU/mL)/(FPG in mmol/L-3.5)\].

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · Percentage (%) of beta-cell function
Homeostasis Model Assessment of Beta-cell Function (HOMA-B)
Percentage (%) of beta-cell functionLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2642.06 ± 73.035.54 ± 72.9
Week 5240.03 ± 79.5—
SecondaryHomeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)

HOMA-IR was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-IR is an index of insulin resistance and was calculated as: HOMA-IR= fasting insulin (μU/mL) x FPG (mmol/L)/22.5.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · HOMA-IR score
Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)
HOMA-IR scoreLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 264.388 ± 81.94.262 ± 73.5
Week 524.567 ± 77.5—
SecondaryTotal Cholesterol

Total cholesterol was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · mg/dL
Total Cholesterol
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 26191.2 ± 17.6194.5 ± 16.1
Week 52190.6 ± 16.3—
SecondaryLow Density Lipoprotein (LDL) Cholesterol

LDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · mg/dL
Low Density Lipoprotein (LDL) Cholesterol
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 26103.4 ± 31.6107.1 ± 27.8
Week 52104.5 ± 26.2—
SecondaryHigh Density Lipoprotein (HDL) Cholesterol

HDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · mg/dL
High Density Lipoprotein (HDL) Cholesterol
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2652.7 ± 25.652.9 ± 26.3
Week 5253.3 ± 24.7—
SecondaryVery Low Density Lipoprotein (VLDL) Cholesterol

VLDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · mg/dL
Very Low Density Lipoprotein (VLDL) Cholesterol
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2626.8 ± 56.727.8 ± 49.4
Week 5225.9 ± 55.2—
SecondaryTriglycerides

Triglycerides were evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · mg/dL
Triglycerides
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 26135.4 ± 60.1142.3 ± 54.9
Week 52130.4 ± 57.0—
SecondaryFree Fatty Acids

Free fatty acids were evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 26 and Week 52
Reported as:
Geometric mean · mg/dL
Free Fatty Acids
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 2612.56 ± 47.412.99 ± 43.9
Week 5212.19 ± 44.3—
SecondaryNumber of Treatment Emergent Adverse Events

Treatment emergent adverse events (TEAEs) were evaluated during the 26-week and 52-week treatment period, respectively. TEAE for weeks 0-26: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 26 + 7 days). TEAE for weeks 0-52: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 52 + 7 days). Hence, the following shown 'Time Frame' should be read as 'Weeks 0-26 + 7 days and Weeks 0-52 + 7 days'.

Time frame:
Weeks 0-26 and Weeks 0-52
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events
EventsLiraglutide 1.8 mgLiraglutide 0.9 mg
Weeks 0-26365266
Weeks 0-52588—
SecondaryNumber of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the 26-week and 52-week treatment period, respectively. Severe or BG confirmed symptomatic hypoglycaemia (hypo):An episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypo. ADA definition of severe hypo:episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk) 0) and no later than 7 days after the last day on liraglutide (maximum till wk 26 and wk 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'wk 0-26+7 days and wk 0-52+7 days'.

Time frame:
Weeks 0-26 and Weeks 0-52
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesLiraglutide 1.8 mgLiraglutide 0.9 mg
Weeks 0-2600
Weeks 0-520—
SecondaryNumber of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the26-week and 52-week treatment period, respectively. Nocturnal hypoglycaemic episodes: Those occurring between 00:01 and 05:59 hours, both inclusive. Severe or BG confirmed symptomatic hypoglycaemia: episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Treatment emergent: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.

Time frame:
Weeks 0-26 and Weeks 0-52
Reported as:
Number · Episodes
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesLiraglutide 1.8 mgLiraglutide 0.9 mg
Weeks 0-2600
Weeks 0-520—
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition

American Diabetes Association (ADA) classification of hypoglycaemia: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG level ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG level ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG level \>3.9 mmol/L with symptoms. Treatment emergent hypoglycaemic episode: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.

Time frame:
Weeks 0-26 and Weeks 0-52
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition
EpisodesLiraglutide 1.8 mgLiraglutide 0.9 mg
Weeks 0-26: Severe hypoglycaemia00
Weeks 0-26: Documented symptomatic hypoglycaemia00
Weeks 0-26: Asymptomatic hypoglycaemia21
Weeks 0-26: Probable symptomatic hypoglycaemia31
Weeks 0-26: Pseudo-hypoglycaemia21
Weeks 0-52: Severe hypoglycaemia0—
Weeks 0-52: Documented symptomatic hypoglycaemia0—
Weeks 0-52: Asymptomatic hypoglycaemia3—
Weeks 0-52: Probable symptomatic hypoglycaemia4—
Weeks 0-52: Pseudo-hypoglycaemia2—
SecondaryChange in Pulse

Change from baseline (week 0) in pulse was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · Beats/minute
Change in Pulse
Beats/minuteLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline80.2 ± 9.880.8 ± 10.4
Week 26: Change from baseline0.8 ± 7.80.2 ± 7.9
Week 52: Change from baseline0.2 ± 8.1—
SecondaryChange in Physical Examination

Reported results are physical examination outcomes at week (wk) 0, wk 26 and wk 52. Physical examination consisted of the following listed examinations and the outcome of each examination was evaluated as: 1) normal, 2) abnormal, not clinically significant (NCS) or 3) abnormal, clinically significant (CS). 1. Cardiovascular system 2. Central and peripheral nervous system (PNS) 3. Gastrointestinal (GI) system including mouth 4. General appearance 5. Head, ears, eyes, nose, throat, neck 6. Lymph node palpation 7. Musculoskeletal system 8. Respiratory system 9. Skin 10. Thyroid gland

Time frame:
Week 0 and Week 26 and Week 52
Reported as:
Count of participants · Participants
Change in Physical Examination
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Cardiovascular system: Wk 0: Normal229230
Cardiovascular system: Wk 0: Abnormal, NCS30
Cardiovascular system: Wk 0: Abnormal, CS13
Cardiovascular system: Wk 26: Normal230229
Cardiovascular system: Wk 26: Abnormal, NCS20
Cardiovascular system: Week 26: Abnormal, CS14
Cardiovascular system: Wk 52: Normal227—
Cardiovascular system: Wk 52: Abnormal, NCS4—
Cardiovascular system: Wk 52: Abnormal, CS2—
Central and PNS: Wk 0: Normal232229
Central and PNS: Wk 0: Abnormal, NCS01
Central and PNS: Wk 0: Abnormal, CS13
Central and PNS: Wk 26: Normal231229
Central and PNS: Wk 26: Abnormal, NCS01
Central and PNS: Wk 26: Abnormal, CS23
Central and PNS: Wk 52: Normal232—
Central and PNS: Wk 52: Abnormal, NCS0—
Central and PNS: Wk 52: Abnormal, CS1—
GI system including mouth: Wk 0: Normal227226
GI system including mouth: Wk 0: Abnormal, NCS04
GI system including mouth: Wk 0: Abnormal, CS63
GI system including mouth: Wk 26: Normal227226
GI system including mouth: Wk 26: Abnormal, NCS03
GI system including mouth: Wk 26: Abnormal, CS64
GI system including mouth: Wk 52: Normal226—
GI system including mouth: Wk 52: Abnormal, NCS2—
GI system including mouth: Wk 52: Abnormal, CS5—
General appearance: Wk 0: Normal229232
General appearance: Wk 0: Abnormal, NCS41
General appearance: Wk 0: Abnormal, CS00
General appearance: Wk 26: Normal229233
General appearance: Wk 26: Abnormal, NCS40
General appearance: Wk 26: Abnormal, CS00
General appearance: Wk 52: Normal229—
General appearance: Wk 52: Abnormal, NCS4—
General appearance: Wk 52: Abnormal, CS0—
Head,ears,eyes,nose,throat,neck: Wk0:Normal225226
Head,ears,eyes,nose,throat,neck: Wk0:Abnormal,NCS32
Head,ears,eyes,nose,throat,neck: Wk0:Abnormal,CS55
Head,ears,eyes,nose,throat,neck: Wk26:Normal225228
Head,ears,eyes,nose,throat,neck: Wk26:Abnormal,NCS41
Head,ears,eyes,nose,throat,neck: Wk26:Abnormal,CS44
Head,ears,eyes,nose,throat,neck: Wk52:Normal223—
Head,ears,eyes,nose,throat,neck: Wk52:Abnormal,NCS5—
Head,ears,eyes,nose,throat,neck: Wk52:Abnormal,CS5—
Lymph node palpation: Wk 0: Normal233233
Lymph node palpation: Wk 0: Abnormal, NCS00
Lymph node palpation: Wk 0: Abnormal, CS00
Lymph node palpation: Wk 26: Normal233233
Lymph node palpation: Wk 26: Abnormal, NCS00
Lymph node palpation: Wk 26: Abnormal, CS00
Lymph node palpation: Wk 52: Normal233—
Lymph node palpation: Wk 52: Abnormal, NCS0—
Lymph node palpation: Wk 52: Abnormal, CS0—
Musculoskeletal system: Wk 0: Normal226231
Musculoskeletal system: Wk 0: Abnormal, NCS40
Musculoskeletal system: Wk 0: Abnormal, CS32
Musculoskeletal system: Wk 26: Normal224230
Musculoskeletal system: Wk 26: Abnormal, NCS50
Musculoskeletal system: Wk 26: Abnormal, CS43
Musculoskeletal system: Wk 52: Normal224—
Musculoskeletal system: Wk 52: Abnormal, NCS5—
Musculoskeletal system: Wk 52: Abnormal, CS4—
Respiratory system: Wk 0: Normal233232
Respiratory system: Wk 0: Abnormal, NCS01
Respiratory system: Wk 0: Abnormal, CS00
Respiratory system: Wk 26: Normal232232
Respiratory system: Wk 26: Abnormal, NCS01
Respiratory system: Wk 26: Abnormal, CS10
Respiratory system: Wk 52: Normal232—
Respiratory system: Wk 52: Abnormal, NCS0—
Respiratory system: Wk 52: Abnormal, CS1—
Skin: Wk 0: Normal225223
Skin: Wk 0: Abnormal, NCS43
Skin: Wk 0: Abnormal, CS47
Skin: Wk 26: Normal218222
Skin: Wk 26: Abnormal, NCS44
Skin: Wk 26: Abnormal, CS117
Skin: Wk 52: Normal224—
Skin: Wk 52: Abnormal, NCS4—
Skin: Wk 52: Abnormal, CS5—
Thyroid gland: Wk 0: Normal232232
Thyroid gland: Wk 0: Abnormal, NCS00
Thyroid gland: Wk 0: Abnormal, CS11
Thyroid gland: Wk 26: Normal232232
Thyroid gland: Wk 26: Abnormal, NCS00
Thyroid gland: Wk 26: Abnormal, CS11
Thyroid gland: Wk 52: Normal232—
Thyroid gland: Wk 52: Abnormal, NCS0—
Thyroid gland: Wk 52: Abnormal, CS1—
SecondaryChange in Eye Examination

Reported results are eye examination (ophthalmoscopy) outcomes at week 0, week 26 and week 52. Ophthalmoscopy outcomes for both left and right eye were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.

Time frame:
Week 0 and Week 26 and Week 52
Reported as:
Count of participants · Participants
Change in Eye Examination
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Left eye - Normal183176
Week 0: Left eye - Abnormal, NCS1513
Week 0: Left eye - Abnormal, CS3544
Week 26: Left eye - Normal178178
Week 26: Left eye - Abnormal, NCS1815
Week 26: Left eye - Abnormal, CS3740
Week 52: Left eye - Normal181—
Week 52: Left eye - Abnormal, NCS16—
Week 52: Left eye - Abnormal, CS36—
Week 0: Right eye - Normal183180
Week 0: Right eye - Abnormal, NCS1411
Week 0: Right eye - Abnormal, CS3642
Week 26: Right eye - Normal176180
Week 26: Right eye - Abnormal, NCS1914
Week 26: Right eye - Abnormal, CS3839
Week 52: Right eye - Normal177—
Week 52: Right eye - Abnormal, NCS18—
Week 52: Right eye - Abnormal, CS38—
SecondaryChange in Electrocardiogram (ECG)

Reported results are ECG outcomes at week 0, week 26 and week 52. ECG outcomes were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.

Time frame:
Week 0 and Week 26 and Week 52
Reported as:
Count of participants · Participants
Change in Electrocardiogram (ECG)
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Normal202196
Week 0: Abnormal, NCS3135
Week 0: Abnormal, CS02
Week 26: Normal205204
Week 26: Abnormal, NCS2626
Week 26: Abnormal, CS23
Week 52: Normal203—
Week 52: Abnormal, NCS28—
Week 52: Abnormal, CS2—
SecondaryChange in Biochemistry: Creatinine

Change from baseline (week 0) in creatinine was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in Biochemistry: Creatinine
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline0.802 ± 0.1440.822 ± 0.164
Week 26: Change from baseline0.018 ± 0.0700.011 ± 0.080
Week 52: Change from baseline0.025 ± 0.078—
SecondaryChange in Biochemistry: eGFR

Change from baseline (week 0) in estimated glomerular filtration rate (eGFR) was evaluated after 26 weeks and 52 weeks of treatment, respectively. eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, mL/min/1.73m\^2.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mL/min/1.73m^2
Change in Biochemistry: eGFR
mL/min/1.73m^2Liraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline78.6 ± 9.577.6 ± 10.7
Week 26: Change from baseline-1.5 ± 5.0-1.0 ± 5.8
Week 52: Change from baseline-2.3 ± 5.6—
SecondaryChange in Biochemistry: Alanine Aminotransferase

Change from baseline (week 0) in alanine aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · U/L
Change in Biochemistry: Alanine Aminotransferase
U/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline32.7 ± 19.534.2 ± 21.8
Week 26: Change from baseline-0.4 ± 12.0-2.2 ± 13.9
Week 52: Change from baseline-2.4 ± 11.9—
SecondaryChange in Biochemistry: Aspartate Aminotransferase

Change from baseline (week 0) in aspartate aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · U/L
Change in Biochemistry: Aspartate Aminotransferase
U/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline26.5 ± 12.826.9 ± 13.9
Week 26: Change from baseline0.2 ± 9.9-1.0 ± 8.6
Week 52: Change from baseline-1.2 ± 8.9—
SecondaryChange in Biochemistry: Alkaline Phosphatase

Change from baseline (week 0) in alkaline phosphatase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · U/L
Change in Biochemistry: Alkaline Phosphatase
U/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline72.5 ± 20.674.1 ± 22.1
Week 26: Change from baseline0.6 ± 9.82.0 ± 12.4
Week 52: Change from baseline2.1 ± 11.1—
SecondaryChange in Biochemistry: Sodium

Change from baseline (week 0) in sodium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mmol/L
Change in Biochemistry: Sodium
mmol/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline140.2 ± 1.9140.2 ± 1.9
Week 26: Change from baseline0.1 ± 1.80.2 ± 2.0
Week 52: Change from baseline0.3 ± 1.8—
SecondaryChange in Biochemistry: Potassium

Change from baseline (week 0) in potassium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mmol/L
Change in Biochemistry: Potassium
mmol/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline4.40 ± 0.344.38 ± 0.34
Week 26: Change from baseline-0.01 ± 0.32-0.02 ± 0.29
Week 52: Change from baseline0.00 ± 0.31—
SecondaryChange in Biochemistry: Albumin

Change from baseline (week 0) in albumin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · g/L
Change in Biochemistry: Albumin
g/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline44.7 ± 2.545.1 ± 2.2
Week 26: Change from baseline-0.2 ± 2.1-0.2 ± 1.9
Week 52: Change from baseline-0.2 ± 2.2—
SecondaryChange in Biochemistry: Total Bilirubin

Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in Biochemistry: Total Bilirubin
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline0.52 ± 0.290.53 ± 0.25
Week 26: Change from baseline0.04 ± 0.250.04 ± 0.24
Week 52: Change from baseline0.06 ± 0.23—
SecondaryChange in Biochemistry: Urea

Change from baseline (week 0) in urea was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in Biochemistry: Urea
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline13.5 ± 3.214.0 ± 3.7
Week 26: Change from baseline0.3 ± 3.0-0.0 ± 3.3
Week 52: Change from baseline0.7 ± 2.8—
SecondaryChange in Biochemistry: Creatine Kinase

Change from baseline (week 0) in creatine kinase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · U/L
Change in Biochemistry: Creatine Kinase
U/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline117.3 ± 61.8129.3 ± 100.3
Week 26: Change from baseline5.2 ± 50.9-5.2 ± 96.3
Week 52: Change from baseline7.5 ± 54.8—
SecondaryChange in Biochemistry: Calcium

Change from baseline (week 0) in calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in Biochemistry: Calcium
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline9.66 ± 0.419.66 ± 0.37
Week 26: Change from baseline-0.01 ± 0.410.01 ± 0.39
Week 52: Change from baseline0.01 ± 0.41—
SecondaryChange in Biochemistry: Albumin Corrected Calcium

Change from baseline (week 0) in albumin corrected calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · mg/dL
Change in Biochemistry: Albumin Corrected Calcium
mg/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline9.28 ± 0.359.26 ± 0.32
Week 26: Change from baseline0.00 ± 0.370.02 ± 0.35
Week 52: Change from baseline0.02 ± 0.36—
SecondaryChange in Biochemistry: Amylase

Change from baseline (week 0) in amylase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · U/L
Change in Biochemistry: Amylase
U/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline62.3 ± 23.161.1 ± 22.5
Week 26: Change from baseline-0.9 ± 12.5-2.3 ± 13.3
Week 52: Change from baseline-0.7 ± 12.1—
SecondaryChange in Biochemistry: Lipase

Change from baseline (week 0) in lipase was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · U/L
Change in Biochemistry: Lipase
U/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline55.4 ± 26.157.3 ± 28.7
Week 26: Change from baseline-1.4 ± 23.4-3.3 ± 26.7
Week 52: Change from baseline-1.0 ± 22.0—
SecondaryChange in Haematology: Haemoglobin

Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · g/dL
Change in Haematology: Haemoglobin
g/dLLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline14.65 ± 1.2614.56 ± 1.35
Week 26: Change from baseline-0.00 ± 0.670.04 ± 0.57
Week 52: Change from baseline-0.00 ± 0.76—
SecondaryChange in Haematology: Haematocrit

Change from baseline (week 0) in haematocrit was evaluated after 26 weeks and 52 weeks of treatment, respectively. Haematocrit is the ratio of the volume of red blood cells to the total volume of blood.

Time frame:
Week 0, Week 26, Week 52
Reported as:
Mean · % of red blood cell
Change in Haematology: Haematocrit
% of red blood cellLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline44.86 ± 3.7944.65 ± 4.03
Week 26: Change from baseline-0.22 ± 2.26-0.06 ± 1.90
Week 52: Change from baseline-0.49 ± 2.39—
SecondaryChange in Haematology: Thrombocytes

Change from baseline (week 0) in thrombocytes (platelets) was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Thrombocytes
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline229.1 ± 47.4231.0 ± 57.6
Week 26: Change from baseline0.8 ± 27.4-1.5 ± 24.2
Week 52: Change from baseline3.4 ± 24.9—
SecondaryChange in Haematology: Erythrocytes

Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^12 cells/L
Change in Haematology: Erythrocytes
10^12 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline4.87 ± 0.414.89 ± 0.43
Week 26: Change from baseline-0.02 ± 0.24-0.00 ± 0.20
Week 52: Change from baseline-0.04 ± 0.25—
SecondaryChange in Haematology: Leukocytes

Change from baseline (week 0) in leukocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Leukocytes
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline6.55 ± 1.716.53 ± 1.58
Week 26: Change from baseline0.09 ± 1.15-0.08 ± 1.09
Week 52: Change from baseline0.09 ± 1.44—
SecondaryChange in Haematology: Eosinophils

Change from baseline (week 0) in eosinophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Eosinophils
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline0.182 ± 0.1430.167 ± 0.158
Week 26: Change from baseline0.001 ± 0.118-0.016 ± 0.104
Week 52: Change from baseline-0.008 ± 0.108—
SecondaryChange in Haematology: Neutrophils

Change from baseline (week 0) in neutrophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Neutrophils
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline3.967 ± 1.3373.975 ± 1.236
Week 26: Change from baseline0.054 ± 1.029-0.088 ± 0.941
Week 52: Change from baseline0.062 ± 1.239—
SecondaryChange in Haematology: Basophils

Change from baseline (week 0) in basophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Basophils
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline0.024 ± 0.0130.026 ± 0.013
Week 26: Change from baseline0.004 ± 0.0170.000 ± 0.016
Week 52: Change from baseline0.000 ± 0.016—
SecondaryChange in Haematology: Monocytes

Change from baseline (week 0) in monocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Monocytes
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline0.341 ± 0.1330.326 ± 0.120
Week 26: Change from baseline0.001 ± 0.101-0.000 ± 0.104
Week 52: Change from baseline0.019 ± 0.153—
SecondaryChange in Haematology: Lymphocytes

Change from baseline (week 0) in lymphocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.

Time frame:
Week 0, Week 26 and Week 52
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Lymphocytes
10^9 cells/LLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Baseline2.034 ± 0.5612.037 ± 0.583
Week 26: Change from baseline0.032 ± 0.3640.022 ± 0.389
Week 52: Change from baseline0.014 ± 0.347—
SecondaryChange in Calcitonin

Reported results are number of subjects with low, normal or high calcitonin values at week 0, week 26 and week 52. Number of subjects analyzed = number of subjects contributed to the analysis for individual time point. Calcitonin values were categorised as low, normal or high.

Time frame:
Week 0 and Week 26 and Week 52
Reported as:
Count of participants · Participants
Change in Calcitonin
ParticipantsLiraglutide 1.8 mgLiraglutide 0.9 mg
Week 0: Low00
Week 0: Normal229229
Week 0: High43
Week 26: Low00
Week 26: Normal228231
Week 26: High52
Week 52: Low0—
Week 52: Normal230—
Week 52: High3—

Adverse events

Collected over Liraglutide 1.8 mg treatment arm: Week 0 to week 52 (treatment period) + 7 days (follow-up period). Liraglutide 0.9 mg treatment arm: Week 0 to week 26 (treatment period) + 7 days (follow-up period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 1.8 mg0/233 (0%)8/233 (3.4%)99/233 (42.5%)
Liraglutide 0.9 mg0/233 (0%)3/233 (1.3%)65/233 (27.9%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLiraglutide 1.8 mgLiraglutide 0.9 mg
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2330/233
Calculus urinaryRenal and urinary disorders0/2331/233
Lacunar infarctionNervous system disorders0/2331/233
Pancreatitis acuteGastrointestinal disorders0/2331/233
CataractEye disorders1/2330/233
Large intestinal polypectomySurgical and medical procedures1/2330/233
Prostatic specific antigen increasedInvestigations1/2330/233
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders1/2330/233
Squamous cell carcinoma of the vaginaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2330/233
Tibia fractureInjury, poisoning and procedural complications1/2330/233
Most frequent other events
Most frequent other events
EventLiraglutide 1.8 mgLiraglutide 0.9 mg
Viral upper respiratory tract infectionInfections and infestations66/23344/233
Diabetic retinopathyEye disorders23/23317/233
ConstipationGastrointestinal disorders17/2335/233
Lipase increasedInvestigations13/2336/233

Baseline characteristics

Full analysis set (FAS), which included all randomised subjects.

Age, Continuous
Age, Continuous(Years)Liraglutide 1.8 mgLiraglutide 0.9 mgTotal
Mean55.07 ± 10.2754.96 ± 10.6155.01 ± 10.43
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 1.8 mgLiraglutide 0.9 mgTotal
Female7768145
Male156165321
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Liraglutide 1.8 mgLiraglutide 0.9 mgTotal
American Indian or Alaska Native000
Asian233233466
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(Percentage (%) of HbA1c)Liraglutide 1.8 mgLiraglutide 0.9 mgTotal
Mean8.14 ± 1.028.10 ± 0.878.12 ± 0.95
09

Study locations

47 sites
  • Novo Nordisk Investigational Site
    Annaka-shi, Gunma, 379 0116, Japan
  • Novo Nordisk Investigational Site
    Chitose, Hokkaido, 066-0032, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku Tokyo, 103-0027, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0002, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0027, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku,, 104 0061, Japan
  • Novo Nordisk Investigational Site
    Fukuoka-shi, Fukuoka, Japan
  • Novo Nordisk Investigational Site
    Higashiosaka-shi, Osaka, Japan
  • Novo Nordisk Investigational Site
    Hokkaido, 078-8236, Japan
  • Novo Nordisk Investigational Site
    Ichikawa-shi, Chiba, Japan
  • Novo Nordisk Investigational Site
    Iruma-shi, Saitama, 358 0011, Japan
  • Novo Nordisk Investigational Site
    Izumisano-shi, 598 0048, Japan
  • Novo Nordisk Investigational Site
    Kashiwara-shi, Osaka, 582 0005, Japan
  • Novo Nordisk Investigational Site
    Kawagoe-shi, Saitama, 350 0851, Japan
  • Novo Nordisk Investigational Site
    Kobe-shi, Hyogo, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi,Kumamoto, 862 0976, Japan
  • Novo Nordisk Investigational Site
    Mito-shi, Ibaraki, 310-0845, Japan
  • Novo Nordisk Investigational Site
    Mito-shi, Ibaraki, Japan
  • Novo Nordisk Investigational Site
    Miyazaki-shi, 880 0034, Japan
  • Novo Nordisk Investigational Site
    Naka-shi, Ibaraki, 311 0113, Japan
  • Novo Nordisk Investigational Site
    Neyagawa-shi, Osaka, Japan
  • Novo Nordisk Investigational Site
    Nishinomiya-shi, Hygo, 662 0971, Japan
  • Novo Nordisk Investigational Site
    Nishinomiya-shi, Hyogo, 663-8501, Japan
  • Novo Nordisk Investigational Site
    Oita-shi, 870 0039, Japan
  • Novo Nordisk Investigational Site
    Okawa-shi, Fukuoka, 831 0016, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 553 0003, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 5590012, Japan
  • Novo Nordisk Investigational Site
    Oyama-shi, Tochigi, 323 0022, Japan
  • Novo Nordisk Investigational Site
    Saga-shi,Saga, 849 0937, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060 0062, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060-0001, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 062 0007, Japan
  • Novo Nordisk Investigational Site
    Sappro-shi, Hokkaido, 060 8648, Japan
  • Novo Nordisk Investigational Site
    Shimotsuke-shi, Tochigi, 329 0433, Japan
  • Novo Nordisk Investigational Site
    Shinjuku-ku, Tokyo, 160-0008, Japan
  • Novo Nordisk Investigational Site
    Shizuoka-shi, 424 0853, Japan
  • Novo Nordisk Investigational Site
    Suita-shi, Osaka, 565-0853, Japan
  • Novo Nordisk Investigational Site
    Takatsuki-shi, Osaka, 569 1096, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 103-0028, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 105-8471, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 123-0845, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 144-0051, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 169-0073, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 181-0013, Japan
  • Novo Nordisk Investigational Site
    Yokohama, Kanagawa, 236-0004, Japan
  • Novo Nordisk Investigational Site
    Yokohama-shi Kanagawa, 232-0064, Japan
  • Novo Nordisk Investigational Site
    Yokohama-shi, 235 0045, Japan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · www.novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in May 2017, 21 months.

Results were first posted in Jun 2018, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2015
First posted
Jul 22, 2015
StartActual
Jul 21, 2015
Primary completionActual
May 2, 2017
CompletionActual
Nov 9, 2017
Results first posted
Jun 25, 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02505334
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 22, 2015
Start date
Jul 21, 2015
Primary completion
May 2, 2017
Completion
Nov 9, 2017
Results posted
Jun 25, 2018
Last update
Sep 5, 2018

Study contacts

Clinical Reporting Anchor and Disclosure 1452
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion